Healthcare Costs Rise with Ozempic and Wegovy
Explore the Ozempic Paradox: discover how weight-loss drugs impact overall healthcare costs despite health improvements.
Weight-Loss Drug Costs Fuel US Employer Healthcare Cuts
More than half of large employers in the United States are planning to reduce their healthcare benefits in 2026. This decision comes as the skyrocketing cost of new weight-loss and specialty medicines puts unprecedented pressure on budgets. The soaring costs of weight-loss drugs are a key concern, according to a new survey. The report, released…...
Ozempic and Mounjaro are reshaping South Africa’s health market
Understand the significance of Ozempic and Mounjaro in the evolving landscape of diabetes care and weight management in South Africa.
GLP-1 drugs increase healthcare costs for obese patients
Healthcare costs for US obesity patients rise with GLP-1 drugs despite their weight-loss benefits.
As competition heats up, Novo Nordisk’s share price declines
Novo Nordisk's share price dropped 19% amidst growing competition from Eli Lilly in the diabetes and weight-loss drug market.
Low long-term adherence to weight loss drugs
Only 25% of US patients prescribed Wegovy or Ozempic for weight loss continued usage after two years, raising concerns about long-term adherence.